Tuberculosis/HIV co-treatment Conditional cash transfers

Slides:



Advertisements
Similar presentations
Antiretroviral Therapy Standard Core Indicators. Emergency Plan for AIDS Relief 2 million people reached with ART 7 million new infects prevented 10 million.
Advertisements

Estimating and Projecting National HIV/AIDS Epidemics UNAIDS Reference Group on Estimates, Models and Projections.
Ani Shakarishvili, MD UNAIDS Country Coordinator in Ukraine AIDS 2012, Washington, DC – 23 July, 2012 Ensuring the financial sustainability of the national.
PEPFAR Emmanuel Njeuhmeli, MD, MPH, MBA Senior Biomedical Prevention Advisor and Co-Chair PEPFAR Male Circumcision Technical Working Group Office of HIV/AIDS.
People receiving antiretroviral therapy, 2005 to June 2014, all countries.
David Wilson Cost-effectiveness of HIV financing.
AIDS 2014 – Ending the adolescent AIDS epidemic Ungdom og hiv Anne May Andersen, Norad.
2,100,000 Number of pregnant women with HIV/AIDS 200,000Number of pregnant women receiving PMTCT 630,000Number of MTCT new infections 2,000,000Number of.
9.7 million people on ART by end of
DPG-AIDS Welcome Michelle Roland, Lead On behalf of DPG-AIDS.
EMTCT Validation in the Africa Region: Regional Overview and Candidate Countries.
HIV/AIDS: A Global and Regional Perspective AIDS in Post 2015 Development Agenda.
Washington D.C., USA, July 2012www.aids2012.org Estimating the Costs and Impacts of HIV/AIDS Programs for Botswana Examples of the ART Program and.
HIV resource needs case studies: Belarus and Armenia
Achieving maximal health impact with available resources: balancing the science, economics, and politics of HIV Cliff Kerr, Robyn Stuart, Andrew Shattock,
Cost-effectiveness of harm reduction David P Wilson.
Return on investment: How do whole societies benefit from improved services and coverage for key populations? Bradley Mathers Kirby Institute UNSW Australia.
Millennium Development Goals Carla AbouZahr Coordinator, Statistics, Monitoring and Analysis Department of Health Statistics and Informatics World Health.
PEPFAR Cost and Impact of Scaling Up EIMC in Southern and Eastern Africa using the DMPPT 2.0 Model AIDS 2014 – Stepping Up The Pace Emmanuel Njeuhmeli,
The National HIV Counselling and Testing Campaign and Treatment Expansion in South Africa: A return on investments in combination prevention XIX International.
The Cost and Impact of Scaling-up Medical Male Circumcision in Uganda: An Empirical Analysis International AIDS Conference Vienna July 2010 Nazarius Mbona.
India Last updated: January 2016.
Getting more value for money: working with countries and partners toward greater effectiveness and efficiency Peter Stegman, Senior Economist.
Towards an improved investment approach for an effective response to HIV Dr Bernhard Schwartländer UNAIDS.
HIV and AIDS Data Hub for Asia-Pacific Review in slides India Last updated: March 2016.
Moving from a commodity approach: “Fund some of everything” or “Fund what is comfortable” to An Investment approach: “Fund evidenced-based activities.
BURUNDI PERMANENT EXECUTIVE SECRETARIAT (SEP) NATIONAL AIDS COUNCIL (C N L S) Epidemic situation and national response for prevention in Burundi PRESENTED.
Expanded PrEP implementation in NSW (EPIC-NSW) 1 AIDS 2016 | 22 July 2016.
VMMC Age and Geographic Prioritization Dr. Katharine Kripke Avenir Health Satellite Session AIDS 2016: Voluntary Medical Male Circumcision (VMMC) as Primary.
Peter D Ghys*, Mary Mahy*, Jeff Eaton**, Samir Bhatt**,
20:20 Vision Making new and old money work better
Contents Global impact 2.Service cascade 3. Policies and WHO support.
Overview of the trends in reducing HIV transmission and incidence
Thailand’s HIV and AIDS STRATEGY
Mongolia Last updated: April 2016.
Scale-up of Antiretroviral Therapy and Preexposure Prophylaxis in Swaziland Eugene T. Richardsona, Futhi Dennisb, Nokwazi Mathabelab, Khanya Mabuzab, Allen.
Ambassador Deborah L. Birx, MD
Conclusions Background Results Acknowledgements: Methods
How were funds spent and what did the study recommend?
HIV surveillance in Northern Ireland 2015
Pakistan Last updated: July 2015.
Adolescents (10-19 yr) Last updated: October 2017.
HIV PREVENTION TARGETS FOR ZIMBABWE
Initiatives in HIV.
AIDS: the long term view Peter Piot
HIV Trends Among Youth Ages in 23 Countries
Finding the right target population for PrEP The cost-effectiveness of PrEP provision to adolescents and young women in South Africa Gesine Meyer-Rath1,2,
Edward Mbizo Sibanda, (MSc) Right to Care
Adolescents (10-19 yr) Last updated: November 2018.
Evaluating the cost-effectiveness of the test and treat program in Zimbabwe
EMMANUEL NJEUHMELI, MD, MPH, MBA
Global Optimization of the Response to HIV
China 2010 UNGASS Country Progress Report
The HIV Epidemic among People who Inject Drugs
Papua New Guinea Last updated: August 2018.
AIDS-related deaths the lowest this century
Brian Weir Johns Hopkins University
Hidden Opportunities - What Will It Take to Reach in Eastern Europe?
Petchsri Sirinirund Advisor to HIV/AIDS Policy and Programme
Key Affected Populations
2005 Country progress towards 2001 Declaration of Commitment
Summary Sheet Figures and Maps
Summary Sheet Figures and Maps
Papua New Guinea.
SETTING TARGETS TO DRIVE DECISIONS MAKING AND ACOUNTABILITY
Contents Global impact 2.Service cascade 3. Policies and WHO support.
Progress on Voluntary Medical Male Circumcision for HIV prevention and How VMMC fits into UNAIDS ' ' target Julia Samuelson, Nurse epidemiologist.
Summary Sheet Figures and Maps
Japan Last updated: April 2019.
Progress on scaling up HIV prevention
Presentation transcript:

Tuberculosis/HIV co-treatment Conditional cash transfers OPTIMIZING HIV INVESTMENT IN SWAZILAND: MODELLING HIGH-IMPACT INTERVENTIONS Sherrie L Kelly,1 Andrew J Shattock,1 Cliff C Kerr,1 David P Wilson,1 Thembi Gama,2 Nokwazi Mathabela,2 Nuha Ceesay,3 Marelize Gorgens4  1The Kirby Institute, 2Swaziland Government/NERCHA, 3UNAIDS, 4World Bank INTRODUCTION METHODS Swaziland has the highest global HIV prevalence with an estimated 27% of people aged 15–49 years living with HIV. To address this issue, the Government aimed to optimize HIV investment by assessing the impact of key interventions. We used to assess the impact of moderate- and high-intensity scale-up of five interventions scaling-up or implementing: Data were provided by the Swaziland Government for general and key populations disaggregated by age and sex for 2000−2013. Assumptions of efficacy, effectiveness, and cost of each intervention are available at optimamodel.com/pubs/swaziland-report.pdf INTERVENTION CURRENT COVERAGE MODERATE INTENSITY COVERAGE TARGETS HIGH NTENSITY COVERAGE TARGETS ART (CD4 count <500 cells/mm3) 2014 2015 2018 2020 2030 55% 65% 75% 85% 90% VMMC (males aged 10−49 years) 19% 45% 70% PMTCT (reduction of breastfeeding (BF) in HIV-positive mothers) 84% BF 30% BF 20% 95% BF 0% Tuberculosis/HIV co-treatment 73% Conditional cash transfers (females aged 15–24 years) 0% 60% 210,000 estimated number of people living with HIV 27% people aged 15–49 years living with HIV SWAZILAND RESULTS By 2030, compared to current coverage: The highest impact interventions are ART and VMMC. The discounted cumulative additional program cost of these combined interventions was US$74 million with an incremental cost-effectiveness ratio of US$2,700 per infection averted (for moderate scale-up) and US$309 million with an incremental cost-effectiveness ratio of US$6,300 per infection averted (for high intensity scale-up). INTERVENTION INTENSITY NEW INFECTIONS AVERTED AIDS-RELATED DEATHS AVERTED Moderate 27% 12% High 49% 24% A Figure 2: Estimated percent contribution of moderate scale-up interventions in reducing new HIV infections and AIDS-related deaths by 2030 CONCLUSION To inform the Swaziland Government in HIV program planning, our analysis showed that rapid scale-up of ART and VMMC would yield the greatest impact on reducing new HIV infections and AIDS-related deaths. B C Figure 1: Epidemic trajectories for scale-up of (A) all interventions combined, (B) ART, and (C) VMMC compared to current trends of new HIV infections and AIDS-related deaths ACKNOWLEDGEMENTS: This study was funded by the World Bank. SLK received a University International Postgraduate Award from UNSW Australia. DPW received a Senior Research Fellowship from the National Health and Medical Research Council. The Kirby Institute at UNSW Australia is funded by the Australian Government, Department of Health and Ageing. The views expressed in this publication do not necessarily represent the position of the Australian Government. No conflicts of interest declared.